SCHEMBL17951102

SCHEMBL17951102

CCOC(=O)C1CCCN(N=O)C1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.56
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.51
KDM4E B2RXH2 6/20 0.50
RAB9A P51151 1/20 0.50
CYP2C19 P33261 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
POLB P06746 1/20 0.49
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22298940 1.00 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL17951415 0.90 MAPT (0.51) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL10969723 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL17951074 0.80 MAPT (0.58) ALDH1A1SMN1; SMN2KDM4ECYP2C19POLB
SCHEMBL18710345 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL153251 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL12310224 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL12885924 0.79 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL5944062 0.78 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A
SCHEMBL7296851 0.78 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2HTTKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3248980-B1 JAK INHIBITOR WUXI FORTUNE PHARMACEUTICAL CO LTD (CN) 2023-09-06 EP disclosed
CN-111518096-B Janus kinase JAK family inhibitor and preparation and application thereof 江苏威凯尔医药科技有限公司 2022-02-11 CN disclosed
CN-108349977-B JAK inhibitors 无锡福祈制药有限公司 2021-05-25 CN disclosed
CN-111518096-A Janus kinase JAK family inhibitor and preparation and application thereof 江苏威凯尔医药科技有限公司 2020-08-11 CN disclosed
US-10617690-B2 JAK inhibitor Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2020-04-14 US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 US disclosed
US-20170360794-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-12-21 US disclosed
EP-3248980-A1 JAK INHIBITOR Wuxi Fortune Pharmaceutical Co., Ltd (CN) 2017-11-29 EP disclosed
WO-2016116025-A1 JAK INHIBITOR 南京明德新药研发股份有限公司 2016-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360794-A1 JAK INHIBITOR JAK2, JAK1, JAK3 ALDH1A1 1708/4885SMN1; SMN2 4190/4885HTT 2997/4885
US-10617690-B2 JAK inhibitor JAK2, JAK1, JAK3 ALDH1A1 1708/4885SMN1; SMN2 4190/4885HTT 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.